Myasthenia Gravis, MuSK

Neurology
2
Pipeline Programs
1
Companies
1
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Catalyst Pharmaceuticals
FIRDAPSEApproved
amifampridine phosphate
Catalyst Pharmaceuticals
oral2018

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Catalyst Pharmaceuticals
Catalyst PharmaceuticalsCORAL GABLES, FL
1 program
1
1
Amifampridine PhosphatePhase 31 trial
Active Trials
NCT03579966TerminatedEst. Aug 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Catalyst PharmaceuticalsAmifampridine Phosphate

Clinical Trials (1)

NCT03579966Catalyst PharmaceuticalsAmifampridine Phosphate

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

Start: Jun 2018Est. completion: Aug 2022
Phase 3Terminated

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
7h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
7h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
7h ago

Director of Finance

CoMind
London, UK
7h ago

Electronics Engineering Manager

CoMind
London, UK
7h ago

Director of Information Technology

Zavation Medical Products
7h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)